Start here if you're new
what it is
Actinium is developing radiation-based cancer drugs for relapsed or refractory patients treated at large hospitals.
how it gets paid
Last year Actinium Pharma made $100K in revenue.
what just happened
Latest quarter revenue was just $90K, which tells you this is still a funding story, not a sales story.
At a glance
C++ balance sheet — some cracks in the foundation
50/100 earnings predictability — expect surprises
-$1.27 fy2024 eps est
$0M fy2023 rev est
1.7 beta
xvary composite: 33/100 — weak
What they do
Actinium is developing radiation-based cancer drugs for relapsed or refractory patients treated at large hospitals.
The edge here is focus, not proof. Actinium has just 37 employees and $0M of long-term debt, so your bet is a small, specialized team staying alive long enough for data to matter. If Actimab-A works, that lean setup can look smart fast.
How they make money
$100K
annual revenue
total revenue
$100K
n/a
The products that matter
named pipeline asset
atnm-400
abstract data flagged by the company
ATNM-400 is one of the few named assets visible on this page. That alone makes it important, because a small biotech with thin revenue lives and dies by whether individual programs keep moving.
catalyst watch
broader pipeline story
other pipeline data
two abstracts coming
Management said it will present two abstracts covering ATNM-400 and other pipeline data. That is not commercialization. It is another attempt to keep the scientific case doing the heavy lifting.
science first
current reality check
no marketed product
$90K revenue
This is the contrast that matters. The pipeline carries the narrative, but current revenue barely exists. If you buy the stock, you are buying what the next milestones might prove.
speculative
Key numbers
$0M
2023 revenue est
Revenue → money coming in the door → so what: you are not buying sales today, you are buying a clinical outcome.
−$1.27
2024 EPS est
EPS → profit per share → so what: still expected losses, which keeps financing risk on the table.
1.7
beta
Beta → stock volatility versus the market → so what: this name tends to move about 70% more than the market.
$0M
long-term debt
Long-term debt → borrowed money due later → so what: the balance sheet is cleaner than many tiny biotechs, even if the income statement is not.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (1% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for ATNM right now.
source: institutional data · return history unavailable
What just happened
loss widened
Latest quarter revenue was just $90K, which tells you this is still a funding story, not a sales story.
EDGAR shows latest-quarter revenue of $90K and EPS of -$0.90. Consensus data separately lists last reported EPS at -$0.16, but both data sets say the same quiet part out loud: revenue is still near zero.
$90K
revenue (Q)
−$0.90
eps (Q)
n/a
n/a
the number that mattered
$90K matters most because it shows the business still has almost no commercial engine behind the science.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
ATNM is not facing generic biotech risk. It is facing the very specific problem of having almost no present-day business to absorb mistakes. When revenue is $90K, nearly every bad surprise goes straight into valuation.
med
pipeline disappointment
The core story is clinical progress. If ATNM-400 or the broader pipeline fails to impress, there is not a commercial base here to soften the blow.
Impact: the stock is tied to milestone credibility more than to current earnings power.
med
dilution risk, not debt risk
Long-term debt is $0M. That sounds clean. In plain English, debt is not the issue. Paying for development probably is.
Impact: if capital has to be raised on weak terms, existing shareholders feel it fast.
med
lawsuit overhang
The Scott+Scott securities class action adds friction at exactly the wrong time. Small biotech stories need trust. Legal noise makes trust more expensive.
Impact: even if the science is unchanged, the market may demand a wider credibility discount.
med
target optimism outruns evidence
A $5.00 median target on a $1.22 stock creates a lot of narrative air. If milestones slip, that air comes out quickly.
Impact: analyst targets do not protect you if the next readout fails to support the story.
This is a classic binary biotech setup: if the data works, the stock can work; if it does not, the $35M equity story gets very small very fast.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
march 13 earnings call
Expected on March 13, 2026, per company announcement. The number that matters is not revenue. It is what management says about timing, funding, and the next proof point.
pipeline
two abstracts, one credibility test
The company said it will present two abstracts on ATNM-400 and other pipeline data. If the science gets clearer, the story gets sturdier. If it stays vague, the stock will feel it.
legal
securities lawsuit overhang
Scott+Scott's case is still pending in U.S. District Court. In a faith-based small cap, legal overhang can weigh on sentiment longer than you would like.
balance sheet
limited resources and extreme volatility
C++ balance sheet strength, 5 / 100 price stability, and $0M debt tell a specific story: leverage is not the issue, but financing flexibility and stock behavior probably are.
Analyst rankings
earnings predictability
50 / 100
earnings can be harder to predict — expect surprises
analyst coverage
13
in human-speak, that is a lot of wall street attention for a $35m company
median target
$5.00 +310%
the street sees a much higher price. you still need the data to earn it.
xvary composite
33 / 100
low score reflects thin revenue, high volatility, and a lot of faith packed into one ticker
source: institutional data
Institutional activity
institutional ownership data for ATNM is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive